



Report Date **Jul 1, 2019**

Status -

Test Performed: Somatic Panel

Specimen

Accession ID QIAGEN CCP TMB
 MSI Colorectal
 Cancer S3_MS-
 unstable
 Specimen biopsy

Collection Jul 1, 2019

Accession Jul 2, 2019

Primary Tumor Site

Result:

Presumed Positive

71

Significant Variants

6

Therapies Associated with
 Resistance

5

Therapies with Potential
 Clinical Benefit

Biomarker Findings:

Tumor Mutation Burden: 258.9 Mutations/Megabase

Microsatellite Status: MS-unstable

Actionable Variants With Associated Therapies

Gene / Variant	Allelic Fraction	Approved Therapies			Clinical Trials
		Colorectal Cancer	Other Indications	Associated With Resistance	
MSH2 c.529G>T p.E177* Tier 1A Pathogenic	27.0% (of 5298 reads)	nivolumab pembrolizumab	-	-	-

*This is a sample report. Only the first two pages of the detailed report are provided. To view the full report please contact bioinformaticssales@qiagen.com



YOUR LAB

Gene / Variant	Allelic Fraction	Approved Therapies			Clinical Trials
		Colorectal Cancer	Other Indications	Associated With Resistance	
MSH2† c.1738G>T p.E580* Tier 1A Pathogenic	53.0% (of 3438 reads)	nivolumab pembrolizumab	-	-	1
MSH2 c.2272G>A p.D758N Tier 1A Likely Pathogenic	26.0% (of 2878 reads)	nivolumab pembrolizumab	-	-	-
ATM c.742C>T p.R248* Tier 2C Pathogenic	39.0% (of 1769 reads)	-	-	-	6
ATR c.2320delA p.I774fs*5 Tier 2C Pathogenic	7.46% (of 1542 reads)	-	-	-	4
BARD1 c.1518_1519delTGins CA p.V507M Tier 2C Likely Pathogenic	36.0% (of 5767 reads)	-	-	-	1

*This is a sample report. Only the first two pages of the detailed report are provided. To view the full report please contact bioinformaticssales@qiagen.com